Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational study assessing the effectiveness and safety of pembrolizumab in advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) in a real world

Trial Profile

An observational study assessing the effectiveness and safety of pembrolizumab in advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) in a real world

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Nov 2018 New trial record
    • 14 Nov 2018 Results (n=54) presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top